1、OUTLOOK,TRENDS&FUTURE MARKETS FOR SINGLE-USECollaboration,technology&innovation:shaping the Collaboration,technology&innovation:shaping the future of singlefuture of single-use use Tuesday July 11th 2023Big Picture Outlook and TrendsSINGLE USE IS DEFINITELY MAINSTREAMINDUSTRY IS MATURING,GETTING MOR

2、E EFFICIENT EXPECTING ITS SUPPLIERS TO SUPPORT PRODUCTIVITYTop Options for Bioreactor Platforms at Commercial Commercial ScaleScale,2023Estimated Percentage of Facilities Unit Operations that are“Single-Use or Disposable”2023 83%of Chinas Upstream BioManufacturing is Single Use New Bioprocessing is

3、mostly SUS at clinical scale.(Chinas bioprocess industry is mostly new).Source:BioPlans 2nd Annual:Chinas Position in Global BioManufacturing A Comparison of Chinas Emerging Position vs Established Regions Manufacturing Capacity and ProductionSingle-Use Vendor Satisfaction,-Year,Percent

4、ageYear,Percentage-point point Increase in Usage of Increase in Usage of DisposablesDisposablesAll Stages R&D&Manufacture,2006All Stages R&D&Manufacture,(Note:Not growth in sales,this is growth in application first usage within a facility)Post-COVID,Whats Driving the Industry?CAPACITY C

5、ONSTRAINTS ARE RETURNING TO NORMALLOOKING TO SINGLE USE TO ADDRESS CAPACITY CHALLENGESINCREASING EXPENDITURES ON SUS20 Years:Capacity Constraints Trends(2004-2023)COVID Severe Constraints 2021-2022Post-COVID 2023I believe our facility is experiencing production capacity constraints todayKey Areas to

6、 Address to Avoid Capacity Constraints(2006-2023)If this industry is to avoid significant capacity constraints,the most important areas to address are:Changes in Bioprocess Consumables OrderingSuppliers vs Biopharmas PerspectivesBiomanufacturer Facility Changes in Ordering for Bioprocess Supplies 20

7、22-2023End User(Biomanufacturer)Facility Changes in Ordering for Supplies and Consumables(Past 12 Mo)Expected Changes in Use of Bioprocessing Consumables(End Users)Source:BioPlans White Paper,Impact Of Covid-19 On Bioprocessing Supply Chain Hiring,and Inventory,2022(Large and mid-Scale Facilities)SU

8、PPLIERS PERSPECTIVE:CHANGES IN ORDERINGSource:BioPlans White Paper,Impact Of Covid-19 On Bioprocessing Supply Chain Hiring,and Inventory,2022(Large and mid-Scale Suppliers)Suppliers Expecting Increased CompetitionEnd-users Expecting Competition AmongSuppliers to Reduce Prices and ExpendituresSupply

9、chain,availability,and lead-times problems during COVID created competitive opportunities:Secondary,3rd and 4th tier suppliers saw successful market entry and growth.Additional competition=Potential to impact competitive pricingOver 71%of End-user respondents expect increased competition to continue

10、,leading to reduced prices.Top NEW Bioprocessing Expenditure Areas inPast Year(2020-2023)Addressing Competition Competing on something other than priceUpstream NPD Areas Where Suppliers Should Focus Efforts(2010-2023)Novel Bioprocessing Innovations to be Evaluated in Next 12 Mo,2023Most Needed Impro

11、vement Area in Cell Therapy:Customized SUS CT systems is#1 Selected Operational Changes Due to Recent Global Economics(2010-2012,2022-2023)Average Cost/Gram for Primary Recombinant Protein(2017-2023)Average Time(weeks)Between Batch Failures,2009-2023How long ago was the last batch failure at your fa

12、cility(unit)?Vendor Sales to BioManufacturers(All segments)Change in Revenue BioProcess Supplies Through COVIDSummaryBiopharma continues its return to stable,consistent growth COVID challenged the industry,but it appears to be returning to consistent 20-year growth trends Overall demand for bioproce

13、ss supplies remains strong New competitors have arrived:COVID created a more competitive environmentdeal with it.One Research Court,Suite 450 Rockville,MD 20850301 921 Outlook,Trends&Future Markets for Single-UseByLarry WestPublisher,Aspen Alert IntroductionAspen Alert Introduced in 2008 Distributed

14、 Daily to an Opt-In Audience of 50,000+Subscribing Biotechnology and Bioprocessing Professionals Aspen Alert Survey Questions(ASQs)Introduced in 2009 1,195 Questions Asked To Date,200+Specific to Single-UseOutlookResilience Study 2023 Cytiva&Longitude(Financial Times)Conducted in January and Februar

15、y 2023 1,250 Biopharma Executives,Representing 22 Countrieshttps:/ Alert has been Monitoring and Reporting Patent Activity Since 2020 Focused on Bioprocess Patents Awarded by US PTO to Academic Institutions,End Users and SuppliersOutlookOutlookOutlookOutlookOutlookOutlookOutlook Yes CRB,Genentech No

16、 GSK,PfizerTrendsTrendsTrendsTrendsTrendsTrendsTrends Growing Alexion,Genentech,Pfizer Slowing CRB,J&J,PTC BioFuture MarketsFuture Markets Now Pfizer Q1/Q2 2024 GSK Later SanofiFuture MarketsAspen Alert has been Monitoring and Reporting Project Activity Since 2020 Biopharma Projects of Academic Institutions,End Users and Suppliers,w/Emphasis on BiologicsOutlookThank You.Larry WestEC.(435)647-6620